Contents lists available at ScienceDirect

Toxicology Letters

journal homepage: www.elsevier.com/locate/toxlet

Single ingestion of di-(2-propylheptyl) phthalate (DPHP) by male volunteers: DPHP in blood and its metabolites in blood and urine

D. Klein^{a,b,*}, W. Kessler^a, C. Pütz^a, B. Semder^a, W. Kirchinger^c, A. Langsch^d, W. Gries^e, R. Otter^d, A.K.E. Gallien^f, X. Wurzenberger^f, J.G. Filser^a

^a Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

^b Institute for Toxicology and Environmental Hygiene, Technical University of Munich, Biedersteiner Str. 29, 80802 Munich, Germany

^c HSE-Medical Services, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

^d BASF SE, E-CPI/R, Carl-Bosch-Str. 38, 67056 Ludwigshafen, Germany

^e Currenta GmbH & Co. OHG, Rheinuferstr. 7-9, 47829 Krefeld, Germany

^f Fakultät für Chemie und Pharmazie, Ludwig-Maximilians-Universität München, Butenandtstraße 5-13, 81377 München, Germany

ARTICLE INFO

Keywords: Di-(2-propylheptyl) phthalate Metabolites Oral exposure Human Blood Urine

ABSTRACT

Di-(2-propylheptyl) phthalate (DPHP) is used as a plasticizer for polyvinyl chloride products. A tolerable daily intake of DPHP of 0.2 mg/kg body weight has been derived from rat data. Because toxicokinetic data of DPHP in humans were not available, it was the aim of the present work to monitor DPHP and selected metabolites in blood and urine of 6 male volunteers over time following ingestion of a single DPHP dose (0.7 mg/kg body weight). Concentration-time courses in blood were obtained up to 24 h for DPHP, mono-(2-propylheptyl) phthalate (MPHP), mono-(2-propyl-6-hydroxyheptyl) phthalate (OH-MPHP), and mono-(2-propyl-6-oxoheptyl) phthalate (oxo-MPHP); amounts excreted in urine were determined up to 46 h for MPHP, OH-MPHP, oxo-MPHP, and mono-(2-propyl-6-carboxyhexyl) phthalate (cx-MPHP). All curves were characterized by an invasion and an elimination phase the kinetic parameters of which were determined together with the areas under the concentration-time curves in blood (AUCs). AUCs were: DPHP > MPHP > oxo-MPHP > OH-MPHP. The amounts excreted in urine were: oxo-MPHP > OH-MPHP > cx-MPHP > MPHP. The AUCs of MPHP, oxo-MPHP, or OH-MPHP could be estimated well from the cumulative amounts of urinary OH-MPHP or oxo-MPHP excreted within 22 h after DPHP intake. Not considering possible differences in species-sensitivity towards unconjugated DPHP metabolites, it was concluded from a comparison of their AUCs in DPHP-exposed humans with corresponding earlier data in rats that there is no increased risk of adverse effects associated with the internal exposure of unconjugated DPHP metabolites in humans as compared to rats when receiving the same dose of DPHP per kg body weight.

1. Introduction

Di-(2-propylheptyl) phthalate (DPHP), CAS No. 53306-54-0, marketed under the trade name "Palatinol®10-P" among others, is a high molecular weight branched phthalate ester which is used as a plasticizer for polyvinyl chloride (PVC) products. Commercial applications include cables, car interiors, carpet backing, pool liners, roofing membranes or tarpaulins, and consumer products such as shoes and artificial leather (BASF, 2015; CPSC, 2011; NICNAS, 2003). Typical contents of DPHP in end-use products vary between 30 and 60% (w/w) (BfR, 2011; NICNAS, 2003). It was found in toys (10.1–48.2% (w/w); BfR, 2011), food packaging, and medical products (NICNAS, 2003). DPHP, like other plasticizers, is not chemically bound in PVC products so it can be released into the environment. Urine samples of the German

https://doi.org/10.1016/j.toxlet.2018.05.010

0378-4274/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).







Abbreviations: AUC, area under the concentration-time curve in blood; bw, body weight; cx-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-carboxyhexyl) phthalate; cx-MPHP, mono-(2-propyl-6-carboxyhexyl) phthalate; cx-MPHP-d4, ring-deuterated mono-(2-propyl-6-carboxyhexyl) phthalate; DEHP, di-(2-ethylhexyl) phthalate; DPHP(-d4), non- or ring-deuterated di-(2-propylheptyl) phthalate; MEHP, mono-(2-ethylhexyl) phthalate; DPHP, di-(2-propylheptyl) phthalate; DPHP, di-(2-propylheptyl) phthalate; MPHP (-d4), non- or ring-deuterated di-(2-propylheptyl) phthalate; MEHP, mono-(2-ethylhexyl) phthalate; MPHP (-d4), non- or ring-deuterated di-(2-propylheptyl) phthalate; MEHP, mono-(2-ethylhexyl) phthalate; NDHP (-d4), non- or ring-deuterated di-(2-propylheptyl) phthalate; MEHP, mono-(2-propylheptyl) phthalate; NOAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-hydroxyheptyl) phthalate; NOAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-hydroxyheptyl) phthalate; ONAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-hydroxyheptyl) phthalate; ONAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-hydroxyheptyl) phthalate; ONAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-hydroxyheptyl) phthalate; ONAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-coxheptyl) phthalate; ONAEL, non- OC-propyl-6-hydroxyheptyl) phthalate; ONAEL, no observed adverse effect level; OH-MPHP(-d4), non- or ring-deuterated mono-(2-propyl-6-coxheptyl) phthalate; ONAEL, non- OC-propyl-6-oxheptyl) phthalate; ONAEL, non- OC-propyl

^{*} Corresponding author at: Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.

E-mail address: dominik.klein@helmholtz-muenchen.de (D. Klein).

Received 14 February 2018; Received in revised form 16 April 2018; Accepted 8 May 2018




Fig. 1. Metabolic pathway of DPHP (Gries et al., 2012).

Environmental Specimen Bank collected from male and female volunteers (age: 20–30 years) between 1999 and 2012 revealed an increasing DPHP exposure of the general German population (Schütze et al., 2015).

Urinary excretion of DPHP metabolites (Fig. 1) was investigated in volunteers following single ingestion of DPHP. Mono-(2-propyl-6-hydroxyheptyl) phthalate (OH-MPHP) and mono-(2-propyl-6-oxoheptyl) phthalate (oxo-MPHP) were the major metabolites, mono-(2-propylheptyl) phthalate (MPHP) and mono-(2-propyl-6-carboxyhexyl) phthalate (cx-MPHP) were quantitatively of minor relevance (Leng et al., 2014; Wittassek and Angerer, 2008). The relationship between an excreted oxidized metabolite (oxo-MPHP) and the oral dose ingested (Leng et al., 2014) was used when estimating from urinary excretion data a maximum daily intake of $0.32 \,\mu$ g DPHP/kg body weight (bw) for the general German population (Schütze et al., 2015).

Toxicological data of DPHP in humans are not available. In Wistar (Crl:WI(Han)) rats, it was neither a reproductive toxicant nor an endocrine disruptor (BASF, 1995a, 2003, 2009; Furr et al., 2014), unlike some other phthalates. Oral administration of DPHP to rats resulted in increased weights of liver and kidney, peroxisome proliferation in the liver, vacuolation of the adrenal zona glomerulosa, eosinophilia in the proximal tubulus of the kidney, and thyroid hypertrophy/hyperplasia as well as increased basophilic cells of the pituitary gland. A rat-specific peroxisome proliferation was discussed to be related to these effects (BASF, 1995b, 2009; Bhat et al., 2014; Union Carbide, 1997, 1998). It is not known whether the findings resulted from the parent compound or its metabolites. Based on the no-observed-adverse-effect level (NOAEL) of 40 mg/kg bw for subchronic toxicity in rats, a tolerable daily intake for humans of 0.2 mg DPHP per kg bw was derived by UBA (2015) being 625 times higher than the daily intake estimated by Schütze et al. (2015). Bhat et al. (2014) calculated an oral reference dose of 0.1 mg/ kg bw per day using a benchmark response level of 10% (10 mg/kg bw per day) for thyroid hypertrophy/hyperplasia in male adult rats. Both derivations followed a generic approach and took into account the increased sensitivity of the rodent thyroid gland as compared to human thyroid gland. Possible species differences in the internal exposures of DPHP and its metabolites were unknown. In order to fill this gap, we recently determined concentrations of DPHP and its metabolites in blood of male Wistar (Crl:WI(Han)) rats following oral administration of single DPHP doses of 0.7 and 100 mg/kg bw (Klein et al., 2016). The aim of the present work was to monitor corresponding concentrations in blood of volunteers over time following ingestion of a single DPHP dose (0.7 mg/kg bw). Another goal was to establish a correlation between DPHP or its metabolites in blood and metabolites of DPHP in urine.

2. Materials and methods

2.1. Chemicals

Standards of DPHP and its metabolites were used as non-deuterated or as ring-deuterated compounds. In the following, non-deuterated compounds are named DPHP, MPHP, OH-MPHP, oxo-MPHP, cx-MPHP and ring-deuterated compounds are named DPHP-d4, MPHP-d4, OH-MPHP-d4, oxo-MPHP-d4, cx-MPHP-d4. If it is not distinguished between non- and ring-deuterated compounds, the abbreviations are DPHP(-d4), MPHP(-d4), OH-MPHP(-d4), oxo-MPHP(-d4), and cx-MPHP (-d4), respectively.

DPHP (Palatinol*10-P, purity 98%, GC analysis), DPHP-d4 (two batches: purities 84%, GC analysis and > 95%, ¹³C-NMR), MPHP (purity 90%, ¹³C-NMR), and MPHP-d4 (two batches: purities 95%, GC analysis and 75%, ¹³C-NMR) were supplied by BASF SE (Ludwigshafen, Germany). OH-MPHP(-d4), oxo-MPHP(-d4), and cx-MPHP(-d4) were gifts from the Institute of Biomonitoring, Currenta GmbH & Co. OHG (Leverkusen, Germany) and were synthesized at the Institut für Dünnschichttechnologie e.V. (Teltow, Germany). The purity of these compounds was \geq 95% as determined by ¹H-NMR.

Acetonitrile for blood analysis (Promochem picograde) and for urine analysis (supra solv) was purchased from LGC Standards (Wesel, Germany) and from Merck (Darmstadt, Germany), respectively. Water for blood analysis (LCMS grade) and for urine analysis was from Fisher Scientific (Loughborough, United Kingdom) and from a Millipore water cleaning system (Milli-Q, Merck, Darmstadt, Germany), respectively. Heparin-Natrium 25,000 I.E. was from Ratiopharm (Ulm, Germany), beta-glucuronidase (E. coli K12) from Roche Diagnostics (Mannheim, Germany), glacial acetic acid (p.a.) and hydrochloric acid 37% (p.a.) from Merck (Darmstadt, Germany), ammonium acetate (p.a.) from Fluka (Taufkirchen, Germany), and formic acid (99%, ULC/MS) from Biosolve B.V. (Valkenswaard, The Netherlands). All other chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) and were of highest purities available.

2.2. Experimental design

Six healthy male adult volunteers (Table 1) gave written informed consent to participate in the study which was reviewed (project number 5913/13) by the Ethics Commission of the Faculty of Medicine of the Technical University of Munich (Munich, Germany). The volunteers had breakfast between 45 and 140 min before DPHP(-d4) ingestion in order to stimulate intestinal lipase secretion. DPHP(-d4) was ingested as a single dose of 738 \pm 56 µg/kg bw (1.65 \pm 0.13 µmol/kg bw) at 9:00

Volunteer	Body weight (kg)	Age (y)	DPHP(-d4) dose ^a (µg/kg bw)	Breakfast		Lunch		
				Time	Food	Time	Food	
Volunteer 1	83	52	717	08:15 a.m.	Salami sandwich, prezel	11:10 a.m.	Schnitzel, French fries	
Volunteer 2	75	64	639	08:15 .am.	Cheese sandwich	11:10 a.m.	Spaghetti Bolognese	
Volunteer 3	76	56	781	08:15 a.m.	Cheese sandwich, prezel	11:15 a.m.	Schnitzel, French fries	
Volunteer 4	74	30	783	06:40 a.m.	Bacon and eggs	11:15 a.m.	Haunch of pork, tomato mozzarella	
Volunteer 5	90	35	775	08:10 a.m.	Egg sandwich	11:15 a.m.	Two slices of bread, vegetables, fruit salad	
Volunteer 6	108	53	733	08:05 a.m.	Cheese sandwich	11:15 a.m.	Schnitzel with ham and cheese, pasta	

^a Volunteers 1 and 2 ingested DPHP-d4, volunteers 3-6 ingested DPHP; time of intake: 09:00 a.m.

a.m. Volunteers 1 and 2 ingested DPHP-d4, the other four volunteers unlabeled DPHP. Both substances were prepared as emulsions of 7% (w/v) in an aqueous saccharose solution (70% w/v) considering the purities of DPHP and DPHP-d4, respectively. The volunteers took 0.01 ml emulsion/kg bw from a graduated disposable syringe (1 ml). The exact dose was determined by reweighing the syringe. Blood samples of 10 ml were taken from the forearm vein via an indwelling catheter using heparinized disposable syringes 30 min before and 0.25, 0.5, 0.75, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, and 10 h after DPHP(-d4) ingestion. The last blood sample was collected directly from the forearm vein after 24 h. Total urine was collected using screw-capped polypropylene bottles immediately before DPHP(-d4) ingestion and 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10, 12, 14, 18, 22, 26, 30, 34, 38, 42, and 46 h thereafter. Urine samples collected during nighttime were stored at 4-8 °C overnight. Volumes and pH values were determined and the samples were stored at -25 °C. For analysis, the samples were thawed in a refrigerated room at 4 °C. Aliquots of 20 ml were transferred into 50 ml Falcon tubes and sent on ice within one day to the Institute of Biomonitoring, Currenta GmbH & Co. OHG (Leverkusen, Germany).

2.3. Analysis of blood samples

2.3.1. Sample preparation and LC-MS/MS analysis

Sample preparation and analysis by LC–MS/MS were performed at the Helmholtz Zentrum München. The procedure was exactly the same as described for rat blood (Klein et al., 2016). Method validation data are presented in the same publication. The internal standard solution used for the blood samples of volunteers 1 and 2 consisted of DPHP (550 nmol/l acetonitrile) and MPHP, OH-MPHP, and oxo-MPHP (each: 220 nmol/l acetonitrile); the internal standard solution used for the blood samples of volunteers 3, 4, 5, and 6 consisted of DPHP-d4 (550 nmol/l acetonitrile), MPHP-d4, OH-MPHP-d4, and oxo-MPHP-d4 (each: 220 nmol/l acetonitrile). LC–MS/MS signals were not obtained for the standards cx-MPHP-d4 or cx-MPHP for unknown reasons. Consequently, cx-MPHP(-d4) could not be quantified from blood samples.

2.3.2. Calibration and quantification

For constructing calibration curves, blood from untreated subjects was added in aliquots of 0.6 ml to 9 Eppendorf caps (1.5 ml) each containing 60 μ l of an acetonitrile solution consisting of the above described internal standards (either deuterated or non-deuterated) and of the analytes at concentrations of 0, 22, 110, 550, or 1650 nmol/l. The purities of the compounds (see 2.1) were taken into account when preparing the solutions. Analytes were either deuterated or non-deuterated DPHP, MPHP, OH-MPHP, and oxo-MPHP. In order to determine the concentrations of DPHP(-d4), of free monoesters, and of total (sum of free and glucuronidated) monoesters, the 9 Eppendorf caps were subdivided into 3 groups with three caps each as was done with the blood samples of the exposed volunteers before further sample treatment. Each of the 3 blood samples per group was analyzed once and the arithmetic mean of the 3 aliquots was used for quantification. Calibration curves were linear in the concentration range tested with

coefficients of determination (r²) of \geq 0.998 for DPHP(-d4), \geq 0.980 for MPHP(-d4) and OH-MPHP(-d4), and \geq 0.989 for oxo-MPHP(-d4).

The detection limits (nmol/l blood), defined as three times the corresponding background signal, were 5.0 for DPHP(-d4), 0.5 for MPHP, 1.0 for MPHP-d4, 0.3 for OH-MPHP, 1.0 for OH-MPHP-d4, 0.3 for oxo-MPHP, and 2.0 for oxo-MPHP-d4. Blood samples from exposed volunteers showing concentrations above the calibration range were analyzed again after dilution of the solution in the autosampler vial with acetonitrile.

2.4. Analysis of urine samples

2.4.1. Sample preparation

Preparation and analysis of urine samples were performed at the Institute of Biomonitoring, Currenta GmbH & Co. OHG. Creatinine was measured by the Jaffé reaction (Taussky, 1954). For the analysis of DPHP metabolites, aliquots of urine (100 μ l) were transferred into 2 ml-autosampler vials. Then, 5 μ l of beta-glucuronidase, 10 μ l of the internal standard solution (1 mg/l of each deuterated or non-deuterated metabolite in acetonitrile), and 1 ml ammonium acetate buffer (1 mol/l, pH 6.5) were added. The sample vials were incubated at 37 °C overnight. Thereafter, samples were centrifuged at 2200g for 10 min at 10 °C and the supernatants were subjected to LC–MS/MS analysis.

2.4.2. LC-MS/MS analysis

Chromatographic separation was processed on a Waters Acquity UPLC System (Waters, Eschborn, Germany) equipped with a columnswitching device. Five µl of the sample was injected onto a SPE column (Waters XBridge C8 direct connect, $2.1 \text{ mm} \times 30 \text{ mm}$, $10 \mu \text{m}$; Waters, Eschborn, Germany) followed by sample enrichment and cleanup for 0.5 min. Thereafter, the analytes were transferred for 3 min via back flush from the SPE column onto the chromatographic column (Agilent Zorbax Eclipse plus C8, $2.1 \text{ mm} \times 100 \text{ mm}$, $1.8 \mu \text{m}$; Agilent, Waldbronn, Germany). The transfer process was stopped after 3.5 min and the SPE column was disconnected. The time courses of the gradients are given in Supplementary Table 1. Mass spectrometric detection and quantification were carried out on a Waters Xevo TQS triple quadrupole (Waters, Eschborn, Germany) with negative electrospray ionization in the multiple reaction monitoring (MRM) mode and with nitrogen as desolvation and argon as collision gas. The ionization conditions are given in Supplementary Table 2.

2.4.3. Calibration and quantification

Calibration was carried out by spiking $100 \,\mu$ l of water with MPHP (-d4), OH-MPHP(-d4), oxo-MPHP(-d4), and cx-MPHP(-d4) at final concentrations ranging from $0.05 \,\mu$ g/l to $2000 \,\mu$ g/l. All calibration samples were analyzed in exactly the same way as the urine samples. Calibrations were linear at analyte concentrations of between 0.1 and $1000 \,\mu$ g/l; quantification of between 1000 and $2000 \,\mu$ g/l was done by fitting a quadratic curve (r > 0.99 for each analyte). Samples with concentrations above the calibration range were analyzed again after sample dilution with water. The detection limit of all analytes was

0.1 µg/l.

2.4.4. Method validation

Samples of human urine were spiked with DPHP metabolites covering concentrations of 1, 10, and 100 μ g/l for MPHP(-d4) and 1, 10, 100, and 1000 μ g/l for OH-MPHP(-d4), oxo-MPHP(-d4), and cx-MPHP (-d4). The samples were analyzed during the analysis sequences for each volunteer on several days to determine between-day precisions. The within-day precisions were obtained by analyzing pooled urine samples at the same concentrations of each deuterated and unlabeled standard. The samples were analyzed ten times in a row and all samples were quantified against the calibration curves. The samples were spiked with 10 μ g/l of each unlabeled or labeled DPHP metabolite as internal standard. Background levels of unlabeled DPHP metabolites were consistently below 1 μ g/l. Within-day and between-day recoveries for all compounds and concentrations were between 85% and 113%, being in line to the findings reported in Gries et al. (2012).

2.5. Kinetic analysis

Mean concentration-time curves of DPHP(-d4) and its metabolites in blood as well as of total metabolites in urine of the volunteers were obtained by fitting the data with a biexponential function (1) $y = C_1 * e^{-\alpha t} + C_2 * e^{-\beta t}$ using Prism 6 for Mac (GraphPad Software, La Jolla, USA). Kinetic parameters were obtained by first fitting the elimination phase ($C_2 * e^{-\beta t}$). For the metabolites, it was taking into account that (2) $C_1 = -C_2$. These parameters were included into the biexponential function that was then fitted to the data representing the invasion phase in order to obtain the values of the parameter α . The technique is similar to the "curve stripping" procedure in which the exponential phases are extracted one by one, starting with the flattest slope of a semi-logarithmic plot. The time course of DPHP showed a lag phase of 2 h. This phase was fitted by the function (3) $y = C * e^{kt}$. The subsequent time course was fitted by the biexponential function with a time axis offset of 2 h. Here, C_1 was given by: (4) $C_1 = -C_2 + C * e^{k^2}$.

Half-lives of the invasion and the elimination phases are ln2/ α and ln2/ β , respectively. Areas under the concentration-time curves (AUC) in blood of the individual subjects were calculated up to 24 h (AUC₀₋₂₄) using the trapezoidal rule. Mean AUCs up to infinity (AUC_{0- ∞}) were calculated using the parameters of the fitted curves.

3. Results

3.1. DPHP and its metabolites in blood

Concentration-time courses of DPHP(-d4) and its metabolites in blood of the individual subjects after single ingestion of DPHP(-d4) are shown in Fig. 2. Since the monoesters undergo glucuronidation, their concentration-time courses are given for both the free and the total (sum of free and glucuronidated) compounds. The concentrations of all compounds displayed various individual peaks diverging up to one order of magnitude. There was a volunteer-specific pattern concerning the number and the time points (T_{max}) of the peaks. It is noteworthy that the metabolites appeared in the blood always earlier than the parent diester that displayed a lag phase of about 2 h.

In order to enable a general kinetic interpretation, curves were fitted to the concentration-time data of the compounds determined in all volunteers. The concentration-time curves could be described by functions with two exponential terms, that of the diester by an additional exponential term describing the lag-phase (Fig. 3). The parameters of the functions are summarized in Table 2. Maximum fitted concentrations (nmol/l blood) amounted to 116 for DPHP(-d4), 105 for MPHP(-d4), 35 for OH-MPHP(-d4), and 49 for oxo-MPHP(-d4) and were reached after 6.0, 3.0, 4.9, and 5.3 h, respectively. At 24 h after dosage, concentrations of DPHP(-d4), MPHP(-d4), OH-MPHP(-d4), and oxo-MPHP(-d4) had declined to 10%, 4%, 12%, and 14% of their

maximum concentrations, respectively. Half-lives of total and free compounds were identical at both the invasion and the elimination phases. Half-lives of the invasion phase were between 1.1 h for MPHP (-d4) and 3.1 h for oxo-MPHP(-d4). Half-lives of the elimination phase were similar among the compounds varying between 4.1 and 4.6 h (Table 2).

The AUC is a common measure reflecting the internal exposure to a chemical. Table 3 compares the AUCs of DPHP(-d4) and its metabolites normalized for the dose of DPHP(-d4) per kg bw. Large interindividual differences in the AUC₀₋₂₄ were found for all substances; they were most pronounced for the diester with a factor of 32. Interindividual AUC_{0-24} values of the metabolites differed up to 10-fold (oxo-MPHP(-d4)). The percentages of free related to total metabolites were quite similar among the volunteers. The highest AUC₀₋₂₄ was observed for the parent compound followed by its direct metabolite with an AUC₀₋₂₄ (total MPHP(-d4)) of two thirds of that of the diester. The mean AUCs₀₋₂₄ of the secondary total metabolites were considerably lower than those of total MPHP(-d4) and amounted to about 30% (OH-MPHP(-d4)) and 40% (oxo-MPHP(-d4)) of that of DPHP(-d4). The percentages of the free metabolites decreased with increasing oxidation state. Whereas free MPHP(-d4) accounted for about 60% (mean value) of total MPHP(-d4), the mean percentage of free oxo-MPHP(-d4) was less than 5% of total oxo-MPHP(-d4). The mean AUC_{0- ∞} values of DPHP(-d4) and MPHP (-d4) were little smaller than the corresponding AUCs₀₋₂₄. This finding is not surprising considering the different methods of calculating the AUCs and the large standard deviations of the mean AUCs_{0.24}.

3.2. DPHP metabolites in urine

Urinary excretion of DPHP(-d4) metabolites wasrelated to the amount of creatinine in the same sample. The creatinine value (mean \pm SD) from all volunteers and all time points was 1.9 \pm 0.7 g/ day being within the normal range (1.0–2.5 g/day; Manski, 2017). The excretions of the compounds could be described by functions with two exponential terms (Fig. 4); the function parameters are listed in Table 2. Fitted maximum values (µg/g creatinine) amounted to 50 for MPHP (-d4), 1070 for OH-MPHP(-d4), 1920 for oxo-MPHP(-d4), and 47 for cx-MPHP(-d4) and were reached after 3.9, 4.9, 4.5, and 5.4 h, respectively. Forty-two hours after DPHP(-d4) intake, fitted contents of MPHP(-d4), OH-MPHP(-d4), and oxo-MPHP(-d4) were about 1% and that of cx-MPHP(-d4) about 7% of the corresponding maximum value. Half-lives of the invasion phase were similar among the metabolites and ranged between 1.6 and 2.4 h (Table 2). Half-lives of the elimination phase were almost identical for MPHP(-d4), OH-MPHP(-d4), and oxo-MPHP (-d4) with values of slightly more than 5 h; cx-MPHP(-d4) was eliminated considerably slower (half-life: 8.7 h, Table 2).

Cumulative excretion of the metabolites of DPHP(-d4) over time in relation to the dose of DPHP(-d4) are summarized in Table 4. Total urinary excretion was calculated as the sum of all metabolites. After 22 h, total excretion was 90 \pm 6% of that after 46 h. At the latter time point, total excretion differed between 1.93% (volunteer 4) and 10.5% (volunteer 1) of the ingested dose of DPHP(-d4) with a mean value \pm SD of 6.1 \pm 3.4%. The most abundant metabolites were OH-MPHP (-d4) and oxo-MPHP(-d4) contributing to 37% and 60% (mean values) of the summed amounts in urine, respectively. MPHP(-d4) and cx-MPHP(-d4) were the metabolites excreted at the lowest amounts, accounting in sum for less than 4% of the total amount excreted. Considering that only a small portion of the oral dose of DPHP(-d4) was excreted via urine, it is most probable that excretion via the feces represents the major elimination way. The conclusion is supported by findings on the structural homologue di-(2-ethylhexyl) phthalate (DEHP) in marmosets in which up to 66% of the ¹⁴C-labeled oral dose were recovered from the feces (Kurata et al., 2012).




Fig. 2. Concentration-time courses of DPHP(-d4) and its metabolites in venous blood of male volunteers upon single oral intake of DPHP(-d4) (ingested dose: 738 \pm 56 µg/kg bw). Volunteers 1 and 2 ingested DPHP-d4, volunteers 3–6 ingested DPHP. Free compounds: unconjugated metabolites; total compounds: sum of free and glucuronidated metabolites. Symbols: measured data (mean values of 3 determinations); lines: connections between the mean values of the measured data.




Fig. 3. Concentration-time courses of DPHP(-d4) and its metabolites in venous blood of volunteers upon single oral intake of DPHP(-d4) (ingested dose: 738 \pm 56 µg/kg bw). Free compounds: unconjugated metabolites; total compounds: sum of free and glucuronidated metabolites. Symbols: mean values \pm SD (-SD not given if below the lowest value on the y-axis) of the 6 volunteers as calculated from the individual data shown in Fig. 2. Lines: curve fits to the mean values. The parameters of the exponential functions describing the curves are given in Table 2.

3.3. Correlation between DPHP and its metabolites in blood and metabolites in urine

The correlation of $AUCs_{0.24}$ of DPHP(-d4), MPHP(-d4), OH-MPHP (-d4), or oxo-MPHP(-d4) in blood with the amounts of OH-MPHP(-d4)

or oxo-MPHP(-d4) excreted within 22 h in the urine of the volunteers were evaluated by linear regression analysis in order to investigate whether metabolites in urine could be used to predict AUCs of DPHP and metabolites in blood. The 22-h time point was preferred over the 46-h one because, in general, a one-day collection period is more

Table 2

Parameters of the functions^a describing the curve fits of the semi-logarithmic concentration-time courses of DPHP(-d4) and its metabolites in venous blood^b or in urine^c of volunteers and half-lives^d upon single oral intake of DPHP(-d4).

Compound	Invasion phase			Elimination phase				
	C ₁	α	t _{1/2(α)}	C ₂	β	t _{1/2(β)}		
Blood	(nmol/l)	(h^{-1})	(h)	(nmol/l)	(h^{-1})	(h)		
DPHP(-d4) ^e	- 381.3	0.3616	1.9	388.2	0.1587	4.4		
MPHP(-d4), total	-238.2	0.6053	1.1	238.2	0.1686	4.1		
MPHP(-d4), free	-155.1	0.6053	1.1	155.1	0.1686	4.1		
OH-MPHP(-d4), total	-161.0	0.2704	2.6	161.0	0.1496	4.6		
OH-MPHP(-d4), free	- 35.98	0.2704	2.6	35.98	0.1496	4.6		
oxo-MPHP(-d4), total	-400.0	0.2209	3.1	400.0	0.1577	4.4		
oxo-MPHP(-d4), free	-20.46	0.2209	3.1	20.46	0.1577	4.4		
Urine	(µg/g creatinine)	(h^{-1})	(h)	(µg/g creatinine)	(h^{-1})	(h)		
MPHP(-d4), total	-117.9	0.4439	1.6	117.9	0.1306	5.3		
OH-MPHP(-d4), total	- 3734	0.2946	2.4	3734	0.1325	5.2		
oxo-MPHP(-d4), total	-5318	0.3548	2.0	5318	0.1276	5.4		
cx-MPHP(-d4), total	-93.44	0.3602	1.9	93.44	0.0796	8.7		

^a $y = C_1 * e^{-\alpha t} + C_2 * e^{-\beta t}$.

^b See Fig. 3.

^c See Fig. 4.

^d $t_{1/2(\alpha)}$: half-life of the invasion phase; $t_{1/2(\beta)}$: half-life of the elimination phase.

^e Parameters for $t \ge 2h$; additional exponential function for the curve fit for $t \le 2h$; $y = 0.512 * e^{1.3010 * t}$.

Table 5	Tab	le	3
---------	-----	----	---

Areas under the concentration-time curves (AUC) of DPHP(-d4) and its metabolites in blood of	volunteers upon single oral intake of DPH	$IP(-d4)^{a}$.

Parameter	AUC, total compo	ound ^b (nmol*h/l per	µmol DPHP(-d4)/kg bw)	AUC, free compound (% of total compound)			
Individual AUC ₀₋₂₄ ^c	DPHP(-d4)	MPHP(-d4)	OH-MPHP(-d4)	oxo-MPHP(-d4)	MPHP(-d4)	OH-MPHP(-d4)	oxo-MPHP(-d4)
Volunteer 1	3029	1346	564	960	54	13	4.7
Volunteer 2	397	539	231	128	73	11	2.7
Volunteer 3	739	437	172	199	66	28	3.9
Volunteer 4	96	160	123	97	55	27	4.5
Volunteer 5	663	938	422	525	63	27	6.1
Volunteer 6	839	439	164	285	55	24	3.9
Mean AUC ₀₋₂₄ \pm SD	961 ± 1048	643 ± 426	279 ± 175	366 ± 329	61 ± 7.7	22 ± 7.6	4.3 ± 1.1
Mean AUC ₀ d	844	618	291	440	65	22	5.1

^a Volunteers 1 and 2 ingested DPHP-d4, volunteers 3-6 ingested DPHP.

^b Sum of free and glucuronidated compounds.

^c Calculated by using the trapezoidal rule.

 d Calculated by using the curve parameters given in Table 2 and the mean dose of 1.65 μmol DPHP/kg bw.

convenient than a longer one. Urinary MPHP(-d4) and cx-MPHP(-d4) were not considered because their excretion amounted each to less than 2% of the total amount excreted. Fig. 5 shows that urinary OH-MPHP (-d4) correlated well with the AUCs of MPHP(-d4), OH-MPHP(-d4), and oxo-MPHP(-d4) in blood with values of r^2 of 0.9001, 0.8528, and 0.8721, respectively. The correlations based on urinary oxo-MPHP(-d4) were weaker (r^2 between 0.6846 for oxo-MPHP(-d4) in blood and 0.7523 for MPHP(-d4) in blood). The weakest correlations were found for the AUC of DPHP(-d4) (r^2 based on urinary OH-MPHP(-d4) 0.6313, based on urinary oxo-MPHP(-d4) 0.3884; data not shown).

4. Discussion

4.1. DPHP and its metabolites in blood

Previous studies suggested the gastrointestinal tract to be an important site of presystemic hydrolytic metabolism of orally administered phthalates in laboratory animals (DEHP: Albro and Thomas, 1973; Albro et al., 1982; Kessler et al., 2004; DPHP: Klein et al., 2016) and in humans (DEHP: Kessler et al., 2012). The produced ionic monoesters are taken up via the portal blood. Concerning the absorption of the lipophilic and non-ionic diesters in humans, the lymph seems to play an important role (discussed for DEHP in Kessler et al., 2012). According to the present results, the same deduction can be done for

DPHP and MPHP. The early occurrence of MPHP in blood of the volunteers likely results from lipase-catalyzed hydrolysis of the diester in the stomach and the duodenum followed by rapid absorption of the monoester. The lag phase observed for DPHP and the longer half-life of the invasion phase compared to that of MPHP agree with the uptake into the lymph and with the slow lymph flow into the thoracic duct (Lindena et al., 1986).

The concentration-time course of MPHP in the systemic blood depends on the gastrointestinal absorption of MPHP, on the formation of MPHP from systemic DPHP, and on the elimination of MPHP by metabolism and excretion. The maximum concentration of MPHP in blood occurred earlier than that of DPHP, which is consistent with the interpretation that systemic MPHP is initially governed mainly by its formation in stomach and gut. The longer half-lives of the invasion phases of OH-MPHP and oxo-MPHP if compared to that of MPHP suggest that they are formed primarily from systemic MPHP and that firstpass metabolism of MPHP is quantitatively of minor relevance. The almost identical elimination half-lives of all of the compounds imply that elimination kinetics of the DPHP metabolites is determined by the metabolic elimination of systemic DPHP. Glucuronidation of the metabolites obviously does not influence their elimination as is substantiated by the parallel concentration-time courses of total and free metabolites.

Concerning systemic exposures, DPHP showed the largest




Fig. 4. Excretion of DPHP(-d4) metabolites (total compounds) in urine of volunteers upon single oral intake of DPHP(-d4) (ingested dose: $738 \pm 56 \,\mu\text{g/kg}$ bw). Symbols: mean values \pm SD (-SD not given if below the lowest value on the y-axis) of the 6 volunteers. Lines: curve fits to the mean values. The parameters of the exponential functions describing the curves are given in Table 2.

interindividual variation among all compounds, possibly resulting predominantly from differences in intestinal absorption. Despite the interindividual variations, the summed AUCs of OH- and oxo-MPHP were always similar to the AUC of MPHP. This hints to an almost exclusive metabolism of systemic MPHP via omega-1 oxidation, taking into account that MPHP and cx-MPHP are virtually not excreted in the urine of volunteers who ingested DPHP (MPHP: this study; Wittassek and Angerer, 2008; cx-MPHP: this study; Leng et al., 2014; Wittassek et al., 2008). The extent of glucuronidation of each metabolite was similar among all volunteers in spite of the comparatively large interindividual variations in the AUCs by a factor of between about 5 (OH-MPHP) and 10 (MPHP and oxo-MPHP). It can be concluded that glucuronidation was not saturated.

The only other phthalate for which kinetic data were published in human blood is DEHP (Fromme et al., 2012; Kessler et al., 2012). Both DPHP and DEHP are absorbed in a similar way from the gut and have principally the same metabolic pathways. Half-lives of the elimination phase of the parent compounds and of their metabolites are similar, too.

Table	4
Iavie	-

Cumulative urinary excretion of DPHP(-d4) metabolites (% of dose on molar basis) at 22 h and 46 h after single oral intake of DPHP(-d4) ^a .
--

Parameter	MPHP(-d4)		OH-MPHP(-d4)		oxo-MPHP(-d4)		cx-MPHP(-d4)		Total excretion ^b	
Time after intake	22 h	46 h	22 h	46 h	22 h	46 h	22 h	46 h	22 h	46 h
Volunteer 1	0.172	0.180	3.98	4.35	5.29	5.78	0.179	0.215	9.59	10.50
Volunteer 2	0.055	0.071	1.15	1.53	2.15	2.64	0.050	0.072	3.40	4.31
Volunteer 3	0.050	0.054	1.38	1.50	2.11	2.23	0.062	0.076	3.59	3.86
Volunteer 4	0.021	0.023	0.68	0.72	1.08	1.14	0.040	0.044	1.81	1.93
Volunteer 5	0.070	0.074	2.91	3.27	5.23	5.89	0.141	0.172	8.34	9.40
Volunteer 6	0.092	0.097	2.10	2.24	3.84	4.08	0.100	0.118	6.13	6.52
Mean	0.077	0.083	2.03	2.27	3.28	3.63	0.095	0.116	5.48	6.09
SD	0.052	0.054	1.23	1.33	1.77	1.95	0.055	0.066	3.06	3.35

^a Volunteers 1 and 2 ingested DPHP-d4, volunteers 3-6 ingested DPHP.

^b Sum of all four metabolites.




Fig. 5. Correlation of AUCs₀₋₂₄ of DPHP(-d4) metabolites in blood with the amounts of metabolites excreted in urine up to 22 h in volunteers upon single oral intake of DPHP(-d4) (ingested dose: 738 \pm 56 µg/kg bw). Symbols: measured data; lines: linear regressions through the origin.

Total MPHP(-d4) in blood vs. OH-MPHP(-d4) in urine: y = 31.5x, $r^2 = 0.9001$. Total MPHP(-d4) in blood vs. oxo-MPHP(-d4) in urine: y = 19.4x, $r^2 = 0.7523$. Total OH-MPHP(-d4) in blood vs. OH-MPHP(-d4) in urine: y = 13.4x, $r^2 = 0.8528$. Total OH-MPHP(-d4) in blood vs. oxo-MPHP(-d4) in urine: y = 8.3x, $r^2 = 0.7109$. Total oxo-MPHP(-d4) in blood vs. OH-MPHP(-d4) in urine: y = 19.6x, $r^2 = 0.8721$. Total oxo-MPHP(-d4) in blood vs. oxo-MPHP(-d4) in urine: y = 11.8x, $r^2 = 0.6846$.

However, clear differences exist in the systemic availabilities of the primary metabolites MPHP and mono-(2-ethylhexyl) phthalate (MEHP). When relating the mean dose-normalized AUC of MPHP or MEHP to the mean dose-normalized AUC of the corresponding parent diester, an almost 5fold lower internal exposure of free or total MPHP as compared to free or total MEHP becomes evident (calculation for free monoesters: ([AUC₀₋₂₄ of total MPHP * 0.61/AUC₀₋₂₄ of DPHP]/[AUC₀₋ 24 of free MEHP/AUC0-24 of DEHP]; data for DEHP and MEHP from Table 3 in Kessler et al. (2012), data for DPHP and MPHP from Table 3 of the present work). The comparison of the free primary monoesters is of particular interest because free MEHP has been attributed to DEHPdependent adverse effects (summarized in Gentry et al., 2011). The difference in the internal exposure of the monoesters might result from a lower intestinal absorption of MPHP as compared to MEHP or from a lower presystemic lipolytic activity towards DPHP as compared to DEHP. The AUCs of the secondary DPHP metabolites were also lower than those of DEHP (Fromme et al., 2012), which is in agreement with the lower internal exposure of MPHP as compared to MEHP. Unlike MPHP, MEHP is metabolized considerably via side-chain carboxylation as was shown in blood and urine of volunteers after DEHP ingestion (Anderson et al., 2011; Fromme et al., 2012; Koch et al., 2005).

Kinetics of DPHP in humans can be compared with that in rats (Klein et al., 2016), the animal species in which the systemic toxicity of DPHP was investigated (see Introduction). At the same single oral dose of DPHP (normalized to 1 μ mol DPHP/kg bw), its mean AUC_{0- ∞} in human blood was 844 nmol*h/l blood (Table 3). In rat blood the AUC₀. $_{\infty}$ of DPHP was too low to be quantified (≤13 nmol*h/l blood, calculated using the parameters of the curve given in Fig. 2B of Klein et al. (2016) and considering the oral dose of 0.7 mg DPHP/kg bw, i.e.,1.56 $\mu mol/kg$ bw). The $AUCs_{0-\infty}$ of total metabolites were 3.2fold (MPHP), 1.6fold (OH-MPHP), and 4.4fold (oxo-MPHP) higher in blood of humans than in blood of rats (calculated using data from Table 3, in the present work and Table 2 in Klein et al., 2016). In humans, the AUCs of the DPHP metabolites are determined most likely to a large extent by the metabolism of systemic DPHP whereas in rats the AUCs of the metabolites seem to be determined almost exclusively by intestinally formed MPHP that is absorbed via the portal vein. A major species difference in the kinetics of DPHP upon oral intake is obviously related to a lower intestinal hydrolysis and higher absorption in humans as compared to rats. The same explanation for corresponding findings

on the kinetics of DEHP in both species was given in Kessler et al. (2012). Species differences in the AUCs of free DPHP metabolites also result from their degrees of glucuronidation. In rats, AUCs of free metabolites contributed to \geq 95% of total metabolites (Klein et al., 2016); in humans, they decreased with the oxidation state of the metabolites from 65% for MPHP to about 5% for oxo-MPHP (mean values of AUCs₀...). As a consequence, AUCs of free OH-MPHP and free oxo-MPHP were 2.8fold and 4.4fold lower, respectively, in human than in rat blood in spite of the higher AUCs of total metabolites in human blood. The AUC of free MPHP was 2.2fold higher in human blood than in rat blood. Interestingly, Kessler et al. (2012) found the same species difference for free MEHP.

4.2. DPHP metabolites in urine

The excretion of DPHP metabolites in the urine of volunteers upon single oral ingestion of DPHP was also investigated in two earlier studies. Wittassek and Angerer (2008) determined metabolites in total urine of a single male volunteer up to 61 h after the uptake of DPHP. No information was given on the dose of DPHP, on details concerning the oral administration, and on the time course of metabolite excretion. Leng et al. (2014) investigated in 5 male volunteers the time dependence of the urinary excretion of secondary metabolites up to 48 h after ingestion of a DPHP dose of between 0.54 and 0.66 mg/kg bw. An ethanolic solution of the substance was mixed in a coffee or tea containing waffle cup with a chocolate surface that was consumed during breakfast. The kinetics of the metabolites in urine turned out to be similar as in our study as substantiated by comparing mean values of T_{max} (Leng et al., 2014: 3.54–4.05 h; this study: 3.9–5.4 h) and of elimination half-lives (Leng et al., 2014: 6.51-8.16 h; this study: 5.2-8.7 h). In the two earlier studies and in the present one, OH-MPHP and oxo-MPHP were the predominant metabolites. However, the total amounts of metabolites excreted (given as mean molar fractions of the dose of DPHP) were distinctly higher in the earlier studies (Wittassek and Angerer, 2008: 34% after 61 h; Leng et al., 2014: 24.7% after 48 h) than in the present one (6.1% after 46 h). A dose-dependent effect can be excluded since the doses used in the present study and in that of Leng et al. (2014) were almost identical. The quantitative differences in the excretion of metabolites could hint to differences in the bioavailability of DPHP and MPHP resulting from presystemic processes. Hydrolysis of

DPHP and absorption of DPHP and MPHP in the digestive tract could be influenced by the dose vehicle, the fat content of the breakfast, and the time span between breakfast and DPHP intake. Lingual lipase, although contributing only little to the preduodenal lipase activity (Kulkarni and Mattes, 2014; Feher, 2017), might contribute to the hydrolysis of DPHP. Formation and absorption of MPHP in the mouth of those volunteers who ate the DPHP containing waffle cup during breakfast (Leng et al., 2014), could have been a cause for the increased urinary metabolite excretion as compared to the present study in which a bolus dose was swallowed immediately. On the other hand, no larger differences were seen between a bolus intake of the DPHP homologue DEHP (Kessler et al., 2012) and its intake via a piece of bread eaten during breakfast (Anderson et al., 2011). Urinary excretion of DEHP metabolites were quantitatively similar in the two volunteer studies in spite of the different methods of oral DEHP dosing.

4.3. Correlation between DPHP and its metabolites in blood and metabolites in urine

Schütze et al. (2015) quantified OH-MPHP and oxo-MPHP in urine samples of the German Environmental Specimen Bank that were collected between 1999 and 2012. The authors compared the data with the increasing DPHP consumption during this time span. Both metabolites were detected only in the samples from 2009 and 2012. The consumption of DPHP was reflected by an increasing detection frequency of oxo-MPHP but not of OH-MPHP. Consequently, urinary oxo-MPHP was considered as the most conclusive parameter for DPHP exposure. According to the present study, both urinary OH-MPHP and oxo-MPHP are suitable for estimating the AUCs of DPHP metabolites in blood, with urinary OH-MPHP being the more accurate one. However, data on urinary OH-MPHP might not be available because the amounts of OH-MPHP are 1.6fold less than those of oxo-MPHP at the same AUCs of metabolites in blood (see Fig. 5 and Table 4).

5. Conclusions

The following conclusions are drawn from the data presented.

- Experimentally determined concentrations of DPHP metabolites in blood of DPHP-exposed volunteers together with their urinary excretion data enabled to estimate the internal exposure to DPHP metabolites from urinary data upon oral exposure. Without knowledge of the correlation, reliable information on the internal exposure cannot be obtained from urinary data solely as exemplified for MPHP being a major metabolite in blood but only a minor one in urine.
- The comparison of the per dose and kg bw normalized AUCs in blood (a measure of the internal exposure) of free metabolites of DPHP in DPHP-exposed humans with corresponding data in DPHPexposed rats revealed only small differences between both species. Not taking into account possible differences in species-sensitivity, it can be concluded from the comparison of the AUCs that there is no increased risk of adverse effects associated with the internal exposure of free DPHP metabolites in humans as compared to rats when receiving the same dose of DPHP (up to 0.7 mg at least) per kg bw.

Transparency document

The Transparency document associated with this article can be found in the online version.

Acknowledgement

The study was financially supported by BASF SE, Germany.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi: https://doi.org/10.1016/j.toxlet.2018.05.010.

References

- Albro, P.W., Thomas, R.O., 1973. Enzymatic hydrolysis of di-(2-ethylhexyl)phthalate by lipases. Biochim. Biophys. Acta 360, 380–390.
- Albro, P.W., Corbett, J.T., Schroeder, J.L., Jordan, S., Matthews, H.B., 1982. Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ. Health Perspect. 45, 19–25.
- Anderson, W.A., Castle, L., Hird, S., Jeffery, J., Scotter, M.J., 2011. A twenty-volunteer study using deuterium labelling to determine the kinetics and fractional excretion of primary and secondary urinary metabolites of di-2-ethylhexylphthalate and di-isononylphthalate. Food Chem. Toxicol. 49, 2022–2029.
- BASF, 1995a. Report. Study of the Prenatal Toxicity of Dipropylheptylphthalate in Wistar Rats after Oral Administration (Gavage). Project No. 10R0110/94013.
- BASF, 1995b. Subchronic Oral Toxicity Study With Dipropylheptylphthalate in Wistar Rats. Administration in the Diet for 3 Months. Project No. 50C0110/94025.
- BASF, 2003. Report. Palatinol*10-P. Prenatal Development Toxicity Study in Wistar Rats. Oral Administration (Gavage). Project No. 30R0183/02046.
- BASF, 2009. Palatinol*10-P. Two-generation Reproduction Toxicity Study in Wistar Rats, Administration via the Diet. Project No. 70R0183/02087.
- BASF (2015), Plasticizer product range for a sustainable business. Available at: http:// www.plasticizers.basf.com/portal/load/fid266211/2015-03-13_Weichmacherbrosch %C3%BCre_final.pdf, accessed 14.01.2018.
- BfR, Bundesinstitut für Risikobewertung (2011), DPHP in Spielzeug nachgewiesen: BfR bewertet Risiko des Weichmachers. Stellungnahme Nr. 004/2012 vom 28. Juni 2011. Available at: http://www.bfr.bund.de/cm/343/dphp-in-spielzeug-nachgewiesen-bfrbewertet-risiko-des-weichmachers.pdf, accessed 14.01.2018.
- Bhat, V.S., Durham, J.L., English, J.C., 2014. Derivation of an oral reference dose (RfD) for the plasticizer di-(2-propylheptyl)phthalate (Palatinol® 10-P). Reg. Tox. Pharm. 70, 65–74.
- CPSC, US Consumer Product Safety Commission (2011), Toxicity review of di(2-propylheptyl)phthalate. Contract No. CPSC-D-06-0006; Task Order 012.
- Feher, J., 2017. Digestion and absorption of the macronutrients. In: Feher, J. (Ed.), Quantitative Human Physiology - An Introduction, 2nd ed. Academic Press, London, UK pp821–833.
- Fromme H., Völkel W., Filser J.G., Kessler W. (2012), Phthalat-Belastung der Bevölkerung in Deutschland: Expositionsrelevante Quellen, Aufnahmepfade und Toxikokinetik am Beispiel von DEHP und DINP, Band III: Humane Toxikokinetikstudie. Schriftenreihe Umwelt & Gesundheit 04/2012, ed. Umweltbundesamt, Dessau-Roßlau, and Bundesinstitut für Risikobewertung, Berlin,Germany. Available at: http://www. umweltbundesamt.de/sites/default/files/medien/378/publikationen/umwelt_und_ gesundheit_04_2012_conrad_phthalatbelastung_bevoelkerung_band3_a.pdf, Accessed 14.01.2018.
- Furr, J.R., Lambright, C.S., Wilson, V.S., Foster, P.M., Gray Jr, L.E., 2014. A short-term in vivo screen using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to predict disruption of sexual differentiation. Toxicol. Sci. 140, 403–424.
- Gentry, P.R., Clewell 3rd, H.J., Clewell, R., Campbell, J., Van Landingham, C., Shipp, A.M., 2011. Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate. Crit. Rev. Toxicol. 41, 1–72.
- Gries, W., Ellrich, D., Küpper, K., Ladermann, B., Leng, G., 2012. Analytical method for the sensitive determination of major di-(2-propylheptyl)-phthalate metabolites in human urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 908, 128–136.
- Kessler, W., Numtip, W., Grote, K., Csanády, G.A., Chahoud, I., Filser, J.G., 2004. Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono(2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets. Toxicol. Appl. Pharmacol. 195, 142–153.
- Kessler, W., Numtip, W., Völkel, W., Seckin, E., Csanády, G.A., Pütz, C., Klein, D., Fromme, H., Filser, J.G., 2012. Kinetics of di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate in blood and of DEHP metabolites in urine of male volunteers after single ingestion of ring-deuterated DEHP. Toxicol. Appl. Pharmacol. 264, 284–291.
- Klein, D., Kessler, W., Semder, B., Pütz, C., Lichtmannegger, J., Otter, R., Filser, J.G., 2016. Di-(2-propylheptyl) phthalate (DPHP) and its metabolites in blood of rats upon single oral administration of DPHP. Toxicol. Lett. 259, 80–86.
- Koch, H.M., Bolt, H.M., Preuss, R., Angerer, J., 2005. New metabolites of di(2-ethylhexyl) phthalate (DEHP) in human urine and plasma after single oral doses of deuteriumlabelled DEHP. Arch. Toxicol. 79, 367–376.
- Kulkarni, B.V., Mattes, R.D., 2014. Lingual lipase activity in the orosensory detection of fat by humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 306, R879–R885. Kurata, Y., Makinodan, F., Shimamura, N., Katoh, M., 2012. Metabolism of di (2-ethyl-
- Kurata, Y., Makinodan, F., Shimamura, N., Katoh, M., 2012. Metabolism of di (2-ethylhexyl) phthalate (DEHP): comparative study in juvenile and fetal marmosets and rats. J. Toxicol. Sci. 37, 33–49.
- Leng, G., Koch, H.M., Gries, W., Schütze, A., Langsch, A., Brüning, T., Otter, R., 2014. Urinary metabolite excretion after oral dosage of bis(2-propylheptyl) phthalate (DPHP) to five male volunteers - characterization of suitable biomarkers for human biomonitoring. Toxicol. Lett. 231, 282–288.
- Lindena, J., Küpper, W., Trautschold, I., 1986. Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication. J.

Clin. Chem. Clin. Biochem. 24, 19-33.

- Manski, D., 2017. Urologie: Online Lehrbuch f
 ür Ärzte; Diagnose und Therapie urologischer Krankheiten. Accessed 14.01.2018 Available at: https://www. urologielehrbuch.de/kreatinin.html.
- NICNAS, National Industrial Chemicals Notification and Assessment Scheme (2003), Full public report, 1,2-benzenedicarboxylic acid, bis(2-propylheptyl) ester, (Palatinol 10-P), File No. STD/1054.
- Schütze, A., Gries, W., Kolossa-Gehring, M., Apel, P., Schröter-Kermani, C., Fiddicke, U., Leng, G., Brüning, T., Koch, H.M., 2015. Bis-(2-propylheptyl)phthalate (DPHP) metabolites emerging in 24h urine samples from the German Environmental Specimen Bank (1999-2012). Int. J. Hyg. Environ. Health 218, 559–563.
- Taussky, H.H., 1954. A microcolorimetric determination of creatine in urine by the Jaffe reaction. J. Biol. Chem. 208, 853–861.
- UBA, Umweltbundesamt (2015), Monograph on di-2-propylheptyl phthalate (DPHP) -
- human biomonitoring (HBM) values for the sum of metabolites oxo-mono-propylheptyl phthalate (oxo-MPHP) and hydroxy-mono-propylheptyl phthalate (OH MPHP) in adult and child urine. Opinion of the Commission "Human Biomonitoring" of the Federal Environment Agency, Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58, 774–784.
- Union Carbide, 1997. Letter from Union Carbide Corp to USEPA Regarding: bis-2-propylheptyl Phthalate Subchronic Feeding Study in Rats. dated 03/17/1997. Microfiche No. OTS0001292, New Doc ID FYI-OTS-0397-1292.
- Union Carbide, 1998. Support: Letter from Union Carbide Corp to USEPA Regarding: 90day Rat Feeding Study with bis-2-propylheptyl phthalate. dated 01/15/1998. Microfiche No. OTS0001292, New Doc ID FYI-OTS-0198-1292.
- Wittassek, M., Angerer, J., 2008. Phthalates: metabolism and exposure. Int. J. Androl. 31, 131–138.